WCLC 2022 | Novel KRAS-targeting agents on the horizon

Barbara Burtness, MD, Yale Cancer Center, New Haven, CT, talks on new KRAS-targeting agents on the horizon including G12C inhibitors, pan-RAS inhibitors and exon 12 targeting agents. Mechanisms of adaptive resistance currently under investigation will likely be relative to all forms of KRAS inhibitors. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.